Histology
Undifferentiated Carcinoma
CI-CAN-00001624Explore in graph →
46 active trials2 approved drugs5 evidence items
- NCIt
- C3692
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001624Explore in graph →
Clinical trials
162 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (30)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01935973 | Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 1 | 26 | National Cancer Institute (NCI)NIH | 1 | Oct 14, 2020 | clinicaltrials |
| NCT04574817 | Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC) | unknown | Phase 2 | 66 | Taizhou Hanzhong biomedical co. LTDINDUSTRY | 1 | Oct 5, 2020 | clinicaltrials |
| NCT00603941 |
| A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel |
| terminated |
| Phase 1 / Phase 2 |
| 19 |
| Daiichi SankyoINDUSTRY |
| 1 |
| Sep 16, 2020 |
| clinicaltrials |
| NCT00950365 | Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 | 79 | Albert Einstein College of MedicineOTHER | 1 | Sep 16, 2020 | clinicaltrials |
| NCT02726503 | Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer(HOPE) | completed | Phase 2 | 39 | Translational Research Center for Medical Innovation, Kobe, Hyogo, JapanOTHER | 1 | Jun 17, 2020 | clinicaltrials |
| NCT03211117 | Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer | completed | Phase 2 | 3 | Mayo ClinicOTHER | 1 | Mar 25, 2020 | clinicaltrials |
| NCT03305133 | Evaluation of PD-L1 (Programmed Death-Ligand 1) Tumor Expression in Patients With Large-cell Neuroendocrine Carcinoma (NEC)(EPNEC) | completed | — | 86 | Groupe Francais De Pneumo-CancerologieOTHER | 1 | Mar 12, 2020 | clinicaltrials |
| NCT00625846 | Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer | completed | Phase 2 | 152 | National Cancer Institute (NCI)NIH | 5 | Feb 26, 2020 | clinicaltrials |
| NCT02134912 | S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib | terminated | Phase 2 | 1 | SWOG Cancer Research NetworkNETWORK | 1 | Feb 20, 2020 | clinicaltrials |
| NCT00654238 | Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer | completed | Phase 2 | 59 | University of PennsylvaniaOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT02657369 | A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC) | terminated | Phase 2 | 34 | Eisai Inc.INDUSTRY | 5 | Oct 15, 2019 | clinicaltrials |
| NCT01504126 | Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Early Phase 1 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 29, 2019 | clinicaltrials |
| NCT01074411 | Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 1 | 33 | National Cancer Institute (NCI)NIH | 1 | Aug 9, 2019 | clinicaltrials |
| NCT02289144 | Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer | withdrawn | Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Jul 30, 2019 | clinicaltrials |
| NCT00262847 | Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 3 | 1,873 | National Cancer Institute (NCI)NIH | 4 | Jul 23, 2019 | clinicaltrials |
| NCT01459380 | Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 1 | Jul 22, 2019 | clinicaltrials |
| NCT01489371 | EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 1 | 16 | Gynecologic Oncology GroupNETWORK | 1 | Mar 12, 2019 | clinicaltrials |
| NCT00939809 | A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 31 | Gynecologic Oncology GroupNETWORK | 1 | Jan 15, 2019 | clinicaltrials |
| NCT02345460 | Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study | terminated | Phase 2 | 1 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 13, 2018 | clinicaltrials |
| NCT01557959 | Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 45 | Wake Forest University Health SciencesOTHER | 1 | Jun 29, 2018 | clinicaltrials |
| NCT00955305 | Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer | terminated | Phase 2 | 175 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2018 | clinicaltrials |
| NCT00899093 | YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy | terminated | — | 2,500 | Gynecologic Oncology GroupNETWORK | 1 | May 22, 2018 | clinicaltrials |
| NCT01275664 | Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer | terminated | N/A | 4 | Gynecologic Oncology GroupNETWORK | 1 | May 22, 2018 | clinicaltrials |
| NCT01080521 | Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy | completed | — | 247 | Gynecologic Oncology GroupNETWORK | 1 | Apr 12, 2018 | clinicaltrials |
| NCT01440998 | Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer | completed | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Apr 5, 2018 | clinicaltrials |
| NCT01642082 | Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 28 | Gynecologic Oncology GroupNETWORK | 1 | Mar 13, 2018 | clinicaltrials |
| NCT00719303 | Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | unknown | Phase 3 | 1,070 | Gynecologic Oncology GroupNETWORK | 1 | Feb 19, 2018 | clinicaltrials |
| NCT00126568 | Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer | terminated | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Jan 19, 2018 | clinicaltrials |
| NCT01178944 | Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer | completed | Phase 2 | 35 | Roswell Park Cancer InstituteOTHER | 1 | Dec 13, 2017 | clinicaltrials |
| NCT00888173 | Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 45 | Gynecologic Oncology GroupNETWORK | 1 | Dec 6, 2017 | clinicaltrials |
| NCT00570674 | Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck | terminated | Phase 1 / Phase 2 | 29 | Dana-Farber Cancer InstituteOTHER | 0 | Nov 13, 2017 | clinicaltrials |
| NCT01225887 | Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 37 | Gynecologic Oncology GroupNETWORK | 1 | Oct 9, 2017 | clinicaltrials |
| NCT00575952 | Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer | completed | Phase 1 | 27 | Gynecologic Oncology GroupNETWORK | 1 | Aug 24, 2017 | clinicaltrials |
| NCT00004221 | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer | terminated | Phase 2 | 12 | Gynecologic Oncology GroupNETWORK | 1 | Aug 9, 2017 | clinicaltrials |
| NCT01240590 | A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC) | completed | Phase 1 / Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Apr 10, 2017 | clinicaltrials |
| NCT01294306 | MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy | completed | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2016 | clinicaltrials |
| NCT02516774 | A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers(TAM-RT) | withdrawn | Phase 1 | 0 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jan 26, 2016 | clinicaltrials |
| NCT00368992 | S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 110 | National Cancer Institute (NCI)NIH | 1 | Sep 14, 2015 | clinicaltrials |
| NCT01093222 | Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jun 30, 2015 | clinicaltrials |
| NCT00060359 | Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | 32 | Gynecologic Oncology GroupNETWORK | 1 | May 8, 2015 | clinicaltrials |
| NCT02016833 | Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity | completed | — | 15 | PX BiosolutionsINDUSTRY | 1 | Apr 30, 2015 | clinicaltrials |
| NCT02059967 | Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC | withdrawn | Phase 1 | 0 | Virginia Commonwealth UniversityOTHER | 0 | Mar 19, 2015 | clinicaltrials |
| NCT00049543 | Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery | completed | Phase 3 | 503 | National Cancer Institute (NCI)NIH | 1 | Jan 1, 2015 | clinicaltrials |
| NCT00814086 | Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer | completed | Phase 1 | 23 | Gynecologic Oncology GroupNETWORK | 1 | Dec 31, 2014 | clinicaltrials |
| NCT01294293 | TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | completed | Phase 1 | 20 | Gynecologic Oncology GroupNETWORK | 1 | Dec 25, 2014 | clinicaltrials |
| NCT01668823 | Photodynamic Therapy in Treating Patients With Lung Cancer | completed | Phase 1 | 17 | Roswell Park Cancer InstituteOTHER | 1 | Jul 31, 2014 | clinicaltrials |
| NCT00507429 | Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer(FACT) | terminated | Phase 2 / Phase 3 | 80 | Mateon TherapeuticsINDUSTRY | 12 | Jun 9, 2014 | clinicaltrials |
| NCT01701349 | Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer(FACT2) | withdrawn | Phase 3 | 0 | Mateon TherapeuticsINDUSTRY | 0 | May 1, 2014 | clinicaltrials |
| NCT00369551 | Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer | terminated | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Mar 6, 2014 | clinicaltrials |
| NCT00095693 | Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2014 | clinicaltrials |
Data updated 22 days agoSource updated Oct 14, 2020source: clinicaltrials